Proton Pump Inhibitors: all 885 studies that test it

Page 5 of 9. Open to participants first (51), then studies with results posted, then the rest; newest registration first within each.

• Pharmacokinetic Study of Lansoprazole Capsules in Healthy Chinese VolunteerCompletedNCT03488173Phase 1
• Whether Proton Pump Inhibitors, Administered Prior to or After Surgery, Can Reduce the Incidence and/or Severity of Difficulty Swallowing Foods and/or Liquids,Following Anterior Cervical SurgeryWithdrawnNCT03488147Phase 2
• Study in Healthy Subjects to Determine the Effect of Relacorilant on Exposure to Probe Substrates for Cytochrome P450sCompletedNCT03457597Phase 1
• Esomeprazole to Reduce Organ Failure in SepsisCompletedNCT03452865Phase 3
• Phase III Study to Evaluate Safety and Efficacy of Ilaprazole in Patients With NERDCompletedNCT03444883Phase 3
• Treatment Response of Maintenance Dose of Proton Pump Inhibitor in Patients With Nonerosive Gatroesophageal Reflux DiseaseCompletedNCT03436914Not applicable
• Safety Trial of Herbal Melanin in Gastritis PatientsStatus unknownNCT03428568Phase 2
• Tailored Therapy for Helicobacter Pylori Rescue TreatmentCompletedNCT03413020Phase 4
• Single Dose Omeprazole Versus High Dose in High-risk Critically Ill Patients.CompletedNCT03388463Not applicable
• Study to Compare the Bioavailability of Omeprazole 20 mg Before and After Undergoing Surgery for Morbid ObesityCompletedNCT03378960Phase 4
• Re-EValuating the Inhibition of Stress Erosions (REVISE) TrialCompletedNCT03374800Phase 3
• Safety, Pharmacokinetics and Pharmacodynamics of the Two Esomeprazole FormulationsStatus unknownNCT03372850Phase 1
• A Study to Evaluate the Effect of Multiple Doses of CC-90001 on the Pharmacokinetics of Omeprazole, Midazolam, Warfarin, Rosuvastatin, Metformin, Digoxin, and Nintedanib in Healthy Adult SubjectsCompletedNCT03363815Phase 1
• Ilaprazole for the Treatment and Prevention of Peptic Ulcer Bleeding in Chinese PatientsCompletedNCT03362281Phase 3
• IIaprazole for the Treatment and Prevention of Peptic Ulcer Bleeding in Chinese PatientsCompletedNCT03362268Phase 2
• Cardiac Safety of Lansoprazole and Domperidon CombinationWithdrawnNCT03355170Phase 4
• Pharmacokinetics and Safety Studies of Esomeprazole Use in Schizophrenia PatientsCompletedNCT03333603Phase 4
• Efficacy and Safety of Hou Gu Mi Xi in Patients With Peptic Ulcer DiseasesCompletedNCT03320538Not applicable
• The Evaluation of Effectiveness Between Empirical and Guided Therapy for Unexplained Non-Cardiac Chest PainCompletedNCT03319121Phase 2/3
• A Phase 1 Study to Evaluate the Effects of Omeprazole and Famotidine on the Absorption of Telotristat Ethyl in Healthy SubjectsCompletedNCT03302845Phase 1
• A Study to Investigate the Effect of Formulation, Food, and Rabeprazole on the Pharmacokinetics (PK) of GDC-0853 in Healthy ParticipantsCompletedNCT03290703Phase 1
• Proton Pump Inhibitor (PPI, Rabeprazole) Effect On Tablet Formulation Of PalbociclibCompletedNCT03220191Phase 1
• Esomeprazole in Treatment of Early Onset Preeclampsia (ESOPE Trial)CompletedNCT03213639Phase 2/3
• Sequential Versus Quadruple Therapy in the Second-line TreatmentStatus unknownNCT03208426Phase 4
• Effectiveness of Physiologic Testing in PPI Non-RespondersCompletedNCT03202537Early Phase 1
• Effects of Helicobacter Pylori Eradication in Children With Chronic Immune Thrombocytopenic PurpuraStatus unknownNCT03172676Phase 4
• A Study to Evaluate the Effects of Food and Esomeprazole on the Pharmacokinetics of Crizotinib in a Coated Microsphere Formulation.CompletedNCT03137134Phase 1
• 10 vs 14 Days Triple Therapy : H.Pylori Infection EradicationStatus unknownNCT03134378Phase 4
• Effects of Concomitant Administration of BMS-986195 on Methotrexate, Caffeine, Montelukast, Flurbiprofen, Omeprazole, Midazolam, Digoxin, and PravastatinCompletedNCT03131973Phase 1
• Comparing Clinical Efficacy of One-Week Dual Delayed-Release Dexlansoprazole and Esomeprazole for GERD Grade A and BCompletedNCT03128736Phase 4
• Drug-drug Interaction Between Aceclofenac 200 mg and Esomeprazole 20 mg in Healthy Male VolunteersStatus unknownNCT03127046Phase 1
• Intraluminal Therapy for Helicobacter Pylori InfectionCompletedNCT03124420Phase 4
• A Clinical Trial to Evaluate the Safety and Tolerability of Dexlansoprazole Injection in Healthy Chinese Adults（Part 2）Status unknownNCT03120273Phase 1
• Adding Bismuth to Rabeprazole-based First-line Triple Therapy Does Not Improve the Eradication of Helicobacter PyloriCompletedNCT03108287Phase 4
• Drug/Drug Interactions With F901318WithdrawnNCT03095547Phase 1
• Once Daily Dose Dexlansoprazole Quadruple Therapy for Helicobacter PyloriCompletedNCT03087162Phase 4
• Omeprazole 20 mg in Patients With Laryngopharyngeal reflux and Comorbid Chronic RhinosinusitisCompletedNCT03086070Phase 4
• An Open-Label Trial of Dexlansoprazole 60mg for the Relief of Heartburn During the Fasting Month of RamadanCompletedNCT03079050Phase 4
• Study to Assess the Relative Bioavailability of Fixed-Dose Combination (FDC) Tablet (Simeprevir, Odalasvir and AL-335) Compared With Single Agents Administered Together, and to Assess the Effect of Multiple-Dose Lansoprazole or Omeprazole on Single-Dose Pharmacokinetics of SMV, ODV, and AL-335 (FDC)TerminatedNCT03059303Phase 1
• Proton Pump Inhibitor Prevent Dual Antiplatelet Agents Induced Gastrointestinal Ulcer After Coronary Artery Bypass GraftWithdrawnNCT03038009Phase 4
• A Clinical Trial to Evaluate the Safety and Tolerability of Dexlansoprazole Injection in Healthy Chinese Adults (Part 1)CompletedNCT03011125Phase 1
• Study to Evaluate Pharmacokinetic Drug Interactions and Safety of Clarithromycin, Amoxicillin and IlaprazoleCompletedNCT02998437Phase 1
• 10-day Versus 14-day Concomitant PAMC as First-line Treatment Strategy for the Eradication of H. Pylori InfectionCompletedNCT02959255Phase 4
• The Efficacy of Lansoprazole and Domperidone Combination on Intragastric and Intraesophageal AcidityCompletedNCT02958046Phase 4
• Pediatric Intensive Care Ulcer Prophylaxis Pilot TrialCompletedNCT02929563Phase 3
• A Study to Examine the Effect of Omeprazole, Famotidine, and an Acidic Beverage on the Pharmacokinetics of Entinostat in Healthy Adult SubjectsCompletedNCT02922933Phase 1
• Intragastric pH and Bismuth Effect for H. Pylori EradicationCompletedNCT02894892Not applicable
• Factors Influencing the Human Gut Microbiome Profile in Multi-ethnic Groups of the Singapore Community (FAMES)CompletedNCT02893709Not applicable
• Efficacy and Safety of 1-week Triple Therapy With Ilaprazole for the Eradication of Helicobacter PyloriCompletedNCT02873065Phase 4
• Ilaprazole for the Treatment of Gastroesophageal Reflux Disease (GERD) in Chinese PatientsCompletedNCT02860624Phase 3
• Ilaprazole for the Treatment of Duodenal Ulcer in Chinese PatientsCompletedNCT02847455Phase 2/3
• Effect of Proton Pump Inhibitors on Gut Microbiota and Systemic Inflammation in Older AdultsCompletedNCT02844621Early Phase 1
• Effect of Proton Pump Inhibitors on PalpitationsCompletedNCT02826408Not applicable
• This Study Tests the Effect of Risankizumab on the Metabolism in the Liver of Five Additional Drugs to Study Possible Drug Interactions in Patients With Psoriasis With or Without Psoriatic ArthritisCompletedNCT02772601Phase 1
• Treatment Effect Between Dexlansoprazole and Double-dose Lansoprazole in Obesity Patients With Reflux EsophagitisStatus unknownNCT02759393Phase 4
• Pharmacokinetic Drug-Drug Interaction Study of RucaparibCompletedNCT02740712Phase 1
• The Efficacy of Esomeprazole Premedication on Intraoperative Bleeding During Gastric ESDCompletedNCT02730533Not applicable
• Comparison of the Clinical Efficacy of Ketoprofen, Associated or Not With Omeprazole in Lower Third Molar RemovalCompletedNCT02730026Phase 4
• Sup-Icu RENal (SIREN)CompletedNCT02718261Phase 4
• Comparison of Daily Single Dose Triple and Conventional Triple Therapies for Helicobacter Pylori InfectionCompletedNCT02711176Phase 4
• The Effect of Dexrabeprazole on Intragastric and Intraesophageal AcidityCompletedNCT02689999Phase 4
• Endoscopic Tri-Modal Imaging to Distinguish Functional Dyspepsia From Reflux DiseaseCompletedNCT02685150Not applicable
• Bioequivalence Study of Torrent Pharmaceutical Ltd's Esomeprazole Magnesium Delayed Release CapsulesCompletedNCT02680132Phase 1
• BE of Torrent's Esomeprazole Mg DR CapsulesCompletedNCT02680119Phase 1
• Open, Randomised, Multi-center Study of on Demand Versus Continuous Esomeprazole Treatment in Patient With GERDCompletedNCT02670642Phase 3
• The Prospective Study on the Effect of Ilaprazole in Non-erosive Reflux Disease Patients; Focused on Histologic Findings and Inflammatory BiomarkerCompletedNCT02666976Phase 4
• Bioequivalence Study of Torrent Pharmaceuticals Ltd.'s Esomeprazole Magnesium DR Capsules Under Fasting ConditionsCompletedNCT02659683Phase 1
• A Study of GDC-0134 to Determine Initial Safety, Tolerability, and Pharmacokinetic Parameters in Participants With Amyotrophic Lateral SclerosisCompletedNCT02655614Phase 1
• Effects of Ilaprazole on Ulcer Healing Rate and Prevention of Gastrointestinal Bleeding in the Patients Undergone ESD.CompletedNCT02638584Phase 4
• A Drug Interaction Study to Assess the Effect of Omeprazole on the Pharmacokinetics of Ibrutinib in Healthy AdultsCompletedNCT02638116Phase 1
• Proton Pump Inhibitors Use in Patients With PsoriasisWithdrawnNCT02624544Phase 4
• A Two Week Nitazoxanidebased Quadruple RegimenStatus unknownNCT02621359Phase 3
• A Study to Check the Safety of Dexlansoprazole and Learn if it Can Treat Symptomatic Nonerosive Gastroesophageal Reflux Disease in Children 2 to 11 Years OldCompletedNCT02616302Phase 2
• A Study to Check the Safety of Dexlansoprazole and Learn If it Can Heal Erosive Esophagitis (EE) and Keep it Healed in Children 2 to 11 Years OldTerminatedNCT02615184Phase 2
• GERD and Anti-Reflux Therapy Between Able-bodied and SCI IndividualsStatus unknownNCT02584751Phase 1
• PPI And Food Effect Study For PF-06463922 In Healthy VolunteersCompletedNCT02569554Phase 1
• High Dose Dual Therapy (HDDT) for Eradication of Helicobacter Pylori InfectionStatus unknownNCT02553083Phase 4
• Food Effect on the Eradication Rate of H. Pylori With Triple Therapy With EsomeprazoleWithdrawnNCT02552641Phase 4
• iFAAM: The Impact of Proton-pump Inhibitors (Antacids) on Threshold Dose DistributionsCompletedNCT02552537Phase 4
• Personalized Treatment for Refractory H Pylori InfectionCompletedNCT02547025Not applicable
• Bioequivalence of Two Formulations of EsomeprazoleCompletedNCT02543606Phase 4
• Different Dose of Intravenous Omeprazole to Treat Bleeding Ulcer With Adherent ClotCompletedNCT02536989Phase 4
• A Bioequivalence Study of Dexlansoprazole From Doxirazole 60 mg Capsules (Hikma Pharma,Egypt)and Dexilant 60 mg Delayed Release (DR) Capsules (Takeda Pharmaceuticals America Inc., USA)CompletedNCT02529787Phase 1
• To Evaluate Pharmacokinetics and Pharmacodynamics of Z-215 in Healthy Male SubjectsCompletedNCT02509923Phase 1
• Comparison of the Clinical Efficacy of Naproxen, Associated or Not With Esomeprazol, in Lower Third Molar RemovalCompletedNCT02494856Phase 4
• Dexlansoprazole MR in Nonerosive Reflux DiseaseStatus unknownNCT02490449Not applicable
• A Bioequivalence Study of Rabeprazole From Idiazole 20mg DR Tabs (GSK, Egypt) and PARIET 20 mg DR Tabs (JANSSEN, EGYPT)CompletedNCT02477306Phase 1
• PROGRESSive Withdrawal Esomeprazole and Acid-related SymptomsActive, not recruitingNCT02476097Phase 4
• A Study to Investigate the Effect of Increased Gastric pH on the Oral Bioavailability of the Orexin-2 Receptor Antagonist JNJ-42847922 in Healthy ParticipantsCompletedNCT02475161Phase 1
• Eradication of Antibiotic-resistant Bacteria Through Antibiotics and Fecal BacteriotherapyStatus unknownNCT02472600Phase 2
• Long-term Oral Esomeprazole for Prevention of Peptic Ulcer Rebleeding in High-risk PatientsCompletedNCT02456012Phase 4
• A 5-Period, Single Dose, Phase 1 Study in Healthy Elderly Subjects to Assess Relative Bioavailability and Food Effect of Two Oral Formulations of GSK1325756 (Free Base vs HBr Salt) and Food Effect on the HBr Formulation When Given With OmeprazoleCompletedNCT02453022Phase 1
• Phase 1 Dexlansoprazole Delayed-Release Capsules for Acid-Related Disorders in Infants Aged 1 to 11 MonthsWithdrawnNCT02442752Phase 1
• Drug Metabolism and AntidepressantStatus unknownNCT02438072Not applicable
• Study of Nitazoxanide (NTZ) Based New Therapeutic Regimens for Helicobacter PyloriStatus unknownNCT02422706Phase 3
• Dual Therapy With High Doses of Ilaprazole and Amoxicillin for Helicobacter Pylori InfectionCompletedNCT02401477Phase 4
• First-line Antibiotic Therapy for Early-stage HP(+) Gastric Pure DLBCLStatus unknownNCT02388581Phase 2
• The Gastrointestinal Microbiome of Infants With GERD and PPI Therapy: a Pilot StudyCompletedNCT02359604Not applicable
• Effect of BI 1181181 on Midazolam, Warfarin, Omeprazole and DigoxinWithdrawnNCT02345304Phase 1
• Impact of Pantoprazole on 24-H Glycemic Control and on Post-prandial Glucose Excursion in Patients With Type 2 DiabetesStatus unknownNCT02345239Phase 3

← Proton Pump Inhibitors overview